Skip to content

TG Therapeutics Inc Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: November 9, 2026 results vs estimates

TG Therapeutics Inc · E.TGTX.NASDAQ · United States
Use symbol E.TGTX.NASDAQ in our API & Excel add-in to retrieve this data ↓
58.08
(+0.01%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 100%
Trend 100%
Bubble Risk LOW
Realised Volatility (20D) 32.97%

TG Therapeutics Inc Forecast

TG Therapeutics Inc short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 33.0% a year, a typical one-standard-deviation range is 55.38–60.78 over a week, 52.55–63.61 over a month and 38.93–77.23 over a year. (Signals as of 1 Nov 2026.)

TG Therapeutics Inc Price Chart

MacroFinance.ai

TG Therapeutics Inc Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
TG Therapeutics Inc
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
TG Therapeutics Inc
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
TG Therapeutics Inc
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
TG Therapeutics Inc
P/E
85.39x
Mid-range vs own history
QoQ +341.7%
YoY +642.8%
now 85.38859.96 low94.84 high
ⓘP/E As of 22 Nov 2026.See TG Therapeutics Inc returns when P/E looked like now →Opens Return analysis with the filter P/E within ±5% of today
TG Therapeutics Inc
P/S
10.09x
Mid-range vs own history
QoQ −5.5%
YoY +4.3%
now 10.08747.23 low13.05 high
ⓘP/S As of 22 Nov 2026.See TG Therapeutics Inc returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
TG Therapeutics Inc
P/B
15.83x
Mid-range vs own history
QoQ +12.0%
YoY +86.9%
now 15.82896.88 low17.58 high
ⓘP/B As of 22 Nov 2026.See TG Therapeutics Inc returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
TG Therapeutics Inc
EV/EBITDA
48.64x
Mid-range vs own history
QoQ −25.3%
YoY +6.4%
now 48.638634.05 low73.17 high
ⓘEV/EBITDA As of 22 Nov 2026.See TG Therapeutics Inc returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
TG Therapeutics Inc
EV/Sales
10.37x
Mid-range vs own history
QoQ −5.2%
YoY +4.7%
now 10.36567.42 low13.4 high
ⓘEV/Sales As of 22 Nov 2026.See TG Therapeutics Inc returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
TG Therapeutics Inc
FCF Yield
0.9%
Strong vs own history
QoQ +363.9%
YoY −169.2%
now 0.9448-1.53 low0.94 high
ⓘFCF Yield As of 22 Nov 2026.See TG Therapeutics Inc returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
TG Therapeutics Inc
Earnings Yield
1.2%
Mid-range vs own history
QoQ −77.4%
YoY −86.5%
now 1.17111.05 low10.04 high
ⓘEarnings Yield As of 22 Nov 2026.See TG Therapeutics Inc returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
TG Therapeutics Inc
Market Cap
$9.1B
Highest in 5 years
QoQ +6.1%
YoY +76.1%
now 9056.12984,456 low10,059 high
ⓘMarket Cap As of 22 Nov 2026.See TG Therapeutics Inc returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
TG Therapeutics Inc
Net Debt
$250M
High vs own history
QoQ +23.5%
YoY +104.4%
now 249.702118.76 low249.7 high
ⓘNet Debt As of 22 Nov 2026.See TG Therapeutics Inc returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
TG Therapeutics Inc
Net Debt / EBITDA
1.31x
Mid-range vs own history
QoQ −13.3%
YoY +23.1%
now 1.30510.88 low1.59 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See TG Therapeutics Inc returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
TG Therapeutics Inc
Current Ratio
4.50x
Mid-range vs own history
QoQ +5.4%
YoY +17.6%
now 4.49653.82 low5.81 high
ⓘCurrent Ratio As of 22 Nov 2026.See TG Therapeutics Inc returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
TG Therapeutics Inc
Quick Ratio
3.75x
Mid-range vs own history
QoQ +0.9%
YoY +29.9%
now 3.75062.89 low5.12 high
ⓘQuick Ratio As of 22 Nov 2026.See TG Therapeutics Inc returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
TG Therapeutics Inc
Interest Coverage
4.10x
Mid-range vs own history
QoQ +14.7%
YoY −2.8%
now 4.09983.57 low5.42 high
ⓘInterest Coverage As of 22 Nov 2026.See TG Therapeutics Inc returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
TG Therapeutics Inc
Debt / Equity
1.32x
High vs own history
QoQ +5.6%
YoY +215.6%
now 1.31850.4 low1.32 high
ⓘDebt / Equity As of 22 Nov 2026.See TG Therapeutics Inc returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
TG Therapeutics Inc
Piotroski F-Score
5
Mid-range vs own history
QoQ 0.0%
YoY +25.0%
now 54 low5 high
ⓘPiotroski F-Score As of 22 Nov 2026.See TG Therapeutics Inc returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
TG Therapeutics Inc
Altman Z-Score
6.09
Mid-range vs own history
QoQ +11.9%
YoY −16.3%
now 6.09434.37 low8.54 high
ⓘAltman Z-Score As of 22 Nov 2026.See TG Therapeutics Inc returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  19 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  20 members-only factors: Sloan Accruals, Cash-Earnings Gap, Beneish M-Score, Days Sales in Receivables Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for TG Therapeutics Inc, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

TG Therapeutics Inc fundamentals: income statement, balance sheet & cash flow

TG Therapeutics Inc reported revenue of $616.3m and net income of $447.2m in FY2025, the year ended 31 December 2025 — revenue up 87.3% and net income up 1,812.4% on the prior year. Free cash flow was -$25.0m. These figures are as reported in the filings, not restated: 30 fiscal years and 123 quarters of history, back to December 1996. 173 FINRA short-interest settlements are published alongside them, back to June 2019.

Revenue (FY2025)
$616.3m
+87.3%
Net income
$447.2m
+1,812.4%
Gross margin
83.66%
Free cash flow
-$25.0m
+38.4%
Net debt
$181.6m
Shares short (30 Oct 2026)
28.77m
18.89 days to cover
TG Therapeutics Inc income statement, annual, as reported · USD millions unless stated
USD millionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue616.3329.0233.72.86.7
Cost of revenue100.738.514.10.30.8
Gross profit515.6290.5219.52.55.9
Research & development160.294.376.2125.4222.6
Selling, general & admin.232.0154.3122.795.5128.1
Operating income123.341.920.6-218.3-344.8
EBITDA134.449.926.1-213.1-342.0
Interest expense26.724.012.610.25.6
Pre-tax income107.425.613.1-223.8-348.1
Income tax-339.82.20.45.57.5
Net income447.223.412.7-223.8-348.1

Download TG Therapeutics Inc fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.TGTX.NASDAQ&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 30 fiscal years and 123 quarters, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on TG Therapeutics Inc

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

TG Therapeutics Inc Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to TG Therapeutics Inc; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How TG Therapeutics Inc’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how TG Therapeutics Inc behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About TG Therapeutics Inc (United States)

TG Therapeutics Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

Frequently asked questions

What is TG Therapeutics Inc?
TG Therapeutics Inc is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest TG Therapeutics Inc price?
The latest close is 58.08 (1 Nov 2026), +0.01% on the day. The price at the top of the page refreshes during the trading day.
Is TG Therapeutics Inc in an uptrend?
As of 1 Nov 2026, short-term momentum is strongly positive (4 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (8 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is TG Therapeutics Inc?
20-day realised volatility is 33.0% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 9.5% over a month and 4.6% over a week.
What factors affect TG Therapeutics Inc?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to TG Therapeutics Inc, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade TG Therapeutics Inc?
58 backtested tactical asset allocation strategies trade TG Therapeutics Inc through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are TG Therapeutics Inc returns analysed?
The Statistical Distribution of Returns section shows the distribution of TG Therapeutics Inc daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free TG Therapeutics Inc historical data?
In the Free historical data section of this page: the last 10 years of TG Therapeutics Inc daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free TG Therapeutics Inc historical data (last 10 years)

Browse or instantly download the last 10 years of TG Therapeutics Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.TGTX.NASDAQ&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-2063.34
2026-11-1964.88
2026-11-1866.12
2026-11-1762.71
2026-11-1662.76
2026-11-1364.51
2026-11-1264.56
2026-11-1165.76
2026-11-1064.26
2026-11-0963.38
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.